Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study

Sophia Hatziantoniou; Helena C Maltezou; Athanasios Tsakris; Gregory A Poland; Cleo Anastassopoulou

doi:10.1016/j.vaccine.2021.03.073

Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study

Vaccine. 2021 May 6;39(19):2605-2607. doi: 10.1016/j.vaccine.2021.03.073. Epub 2021 Apr 6.

Authors

Sophia Hatziantoniou¹, Helena C Maltezou², Athanasios Tsakris³, Gregory A Poland⁴, Cleo Anastassopoulou⁵

Affiliations

¹ Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.
² Directorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece.
³ Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States.
⁵ Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: cleoa@med.uoa.gr.

No abstract available

Keywords: Allergy; Anaphylaxis; BNT162b2; COVID-19; Excipients; Hypersensitivity; Lipid nanoparticles (LNPs); Polyethylene glycol (PEG); SARS-CoV-2; Spike.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anaphylaxis*
COVID-19 Vaccines
COVID-19*
Humans
RNA, Messenger
SARS-CoV-2

Substances

COVID-19 Vaccines
RNA, Messenger